Cathie Wood and Ark Invest have significantly increased their stake in Tempus AI, with the innovation-focused investment firm acquiring over 600,000 shares across its funds since the start of 2025.
Ark Invest's interest in TEM began on December 6, when the ARK Genomic Revolution ETF made its initial purchase of shares in the healthcare technology company. Since then, Tempus AI has rapidly ascended within Ark's portfolio, becoming the tenth largest holding in the flagship ARK Innovation ETF . TEM now represents 3.2% of ARKK's total assets, with a market value exceeding $265 million.
Additionally, Tempus is the fourth-largest position in the ARK Genomic Revolution ETF, accounting for 5.64% of the fund's portfolio, with a market value nearing $68 million.
In January 2025, Ark Innovation ETF expanded its position in TEM, acquiring 439,536 shares, while ARKG also increased its holdings, purchasing an additional 179,255 shares during the same period.
Tempus AI is currently up 62% year-to-date.
In 2025, Wood’s ARKK is up by 10% and ARKG is up on the year by 17%.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。